These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 26908627)
1. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Bid HK; Phelps DA; Xaio L; Guttridge DC; Lin J; London C; Baker LH; Mo X; Houghton PJ Mol Cancer Ther; 2016 May; 15(5):1018-28. PubMed ID: 26908627 [TBL] [Abstract][Full Text] [Related]
3. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
4. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638 [TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878 [TBL] [Abstract][Full Text] [Related]
8. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC. Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740 [TBL] [Abstract][Full Text] [Related]
9. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473 [TBL] [Abstract][Full Text] [Related]
10. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580 [TBL] [Abstract][Full Text] [Related]
12. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer. Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944 [TBL] [Abstract][Full Text] [Related]
13. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling. Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185 [TBL] [Abstract][Full Text] [Related]
15. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525 [TBL] [Abstract][Full Text] [Related]
16. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532 [TBL] [Abstract][Full Text] [Related]
17. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines. Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508 [TBL] [Abstract][Full Text] [Related]
18. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027 [TBL] [Abstract][Full Text] [Related]
19. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer. Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]